Companies · Biotechnology

Athersys, Inc / New

CLEVELAND · Biotechnology

Diligence memoA one-page analyst read on Athersys, Inc / New — recommendation, valuation, rhythm, risks.
$12.5M
Total raised · real
2
Rounds
0.4×
Latest step-up
Top 41%
Sector rank · raised
Series A
Latest stage · inferred · Tue Apr 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Athersys, Inc / New looks fair against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.75× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era.
  • Within the normal band (75% of peer median) for its niche.
At-risk
  • Last raise 3.2 yr ago; this sector typically re-raises about every 14 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Athersys, Inc / New is one of 4291 Biotechnology companies tracked from CLEVELAND. By capital raised it ranks mid-pack (ahead of 60% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
4
Investors (latest)
2023-04-18
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries A · 2012-03-09 Raised $9.0M (real) Modeled valuation $325M (est)$9.0M$325MSeries A2012Series A · 2023-04-18 Raised $3.5M (real) Modeled valuation $33M (est)$3.5M$33MSeries A2023+$3.5MCumulative $13M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$9.0M · 2012
Series A extension$3.5M · 2023

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$33.2M
Base estimate est.
$3.9M
Conservative case
$94.7M
Upside case
$16.1M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $325.4M · 2012-03-092012Series A · modeled $33.2M · 2023-04-182023
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
3.2 yr
Elapsed time used
3.2 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
133 mo
Avg between rounds
$1.1M/yr
Capital velocity
14.3 yr
On record since
2012
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.7× above median
This company$12.5M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.7× of median
This company$3.5M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 0.5× of median
This company$33.2M
Sector median$64.2M

Raised more than 60% of sector peers (real $). Modeled value above 37% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #188 of 303.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0M$100.0MCapital raised (log)GeoVax Labs, Inc. · Series A Raised $39.1M · modeled $217.0M (est)Cellinfinity Bio Holding Company, LLC · Series A Raised $13.2M · modeled $215.9M (est)Adient Medical, Inc. · Series A Raised $18.2M · modeled $206.8M (est)Entegrion Inc · Series A Raised $22.7M · modeled $191.3M (est)BCD Bioscience, Inc. · Series A Raised $16.4M · modeled $188.9M (est)Pragma Biosciences Inc. · Series A Raised $14.5M · modeled $186.0M (est)MicroByre, Inc. · Series A Raised $16.1M · modeled $185.7M (est)Cardiac Insight, Inc. · Series A Raised $38.1M · modeled $183.8M (est)Cardiac Implants LLC · Series A Raised $13.5M · modeled $178.2M (est)Abintus Bio, Inc. · Series A Raised $13.7M · modeled $177.2M (est)Mosaic Biosciences, Inc. · Series A Raised $14.7M · modeled $176.1M (est)Mazen Animal Health Inc. · Series A Raised $13.5M · modeled $168.8M (est)Athersys, Inc / New (this company) Raised $12.5M · modeled $33.2M (est)Athersys, Inc / New
CompanyStageRaised · realValue · estvs peer med.
GeoVax Labs, Inc.Series A$39.1M$217.0M4.90×
Cellinfinity Bio Holding Company, LLCSeries A$13.2M$215.9M4.87×
Adient Medical, Inc.Series A$18.2M$206.8M4.67×
Entegrion IncSeries A$22.7M$191.3M4.32×
BCD Bioscience, Inc.Series A$16.4M$188.9M4.27×
Pragma Biosciences Inc.Series A$14.5M$186.0M4.20×
MicroByre, Inc.Series A$16.1M$185.7M4.19×
Cardiac Insight, Inc.Series A$38.1M$183.8M4.15×
Cardiac Implants LLCSeries A$13.5M$178.2M4.02×
Abintus Bio, Inc.Series A$13.7M$177.2M4.00×
Mosaic Biosciences, Inc.Series A$14.7M$176.1M3.98×
Mazen Animal Health Inc.Series A$13.5M$168.8M3.81×
Athersys, Inc / New this companySeries A$12.5M$33.2M0.75×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$9.0M2012-03-09$40.9M$325.4M85%
Series A$3.5M2023-04-18$16.1M$33.2M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$9.0M2012-03-09
    • First recorded raise — entered as Series A.
    • 20 investors on this round.
  2. Series A$3.5M2023-04-18
    • Raised again after 133 mo — slower than the ~14 mo sector norm.
    • Round 2.5× smaller than the prior — bridge or down round.
    • Switched to Rule 506(b) (was Rule 06).
    • 4 investors on this round.
Intelligence
2034 ~Q2
Modeled next raise · ~133mo cadence
$3.5M
Modeled next size est.range $3.5M$5.7M
0.4×
Last step-up
$1.1M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Joseph Nolan4 other2023-04
Lorin J Randall2 other2012-03
ISMAIL KOLA1 other2023-04
DANIEL CAMARDO2023-04
George M. Milne2012-03
Gil Van Bokkelen2012-03
Ismail E. Kola2012-03
Jack L. Wyszomlerski2012-03
JACK WYSZOMIERSKI2023-04
JANE WASMAN2023-04
John J. Harrington2012-03
KASEY ROSADO2023-04
Laura K. Campbell2012-03
Lee E. Babiss2012-03
MAIA HANSEN2023-04
William L. Lehmann2012-03
Registry & provenance

Athersys, Inc / New is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1368148
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Nanosphere IncBiotechnologySeries A$4.1M$147.1Mnetwork1 shared operator · same sector · same stage
nference, inc.BiotechnologySeries A$12.3M$32.6Msame sector · same stage
Digital Biotechnologies, Inc.BiotechnologySeries A$12.3M$31.8Msame sector · same stage
Luna Genetics, Inc.BiotechnologySeries A$12.1M$32.3Msame sector · same stage
Alida Biosciences Inc.BiotechnologySeries A$12.0M$40.7Msame sector · same stage
Quellis Biosciences, Inc.BiotechnologySeries A$13.1M$29.7Msame sector · same stage
Panome Bio Inc.BiotechnologySeries A$12.0M$26.3Msame sector · same stage
Parcel Biosciences, Inc.BiotechnologySeries A$13.2M$31.9Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Attralus, Inc.BiotechnologySeries D+$708.5M84%
Atreca, Inc.BiotechnologySeries D+$5.2B84%
Florey Biosciences, Inc.BiotechnologySeed$4.4M83%
New Equilibrium Biosciences, Inc.BiotechnologySeries A$256.3M83%
Newomics Inc.BiotechnologySeed$148.7M83%
Biotricity Inc.BiotechnologySeries A$6.0M83%
NewLimit, Inc.BiotechnologySeries D+$1.1B83%
Peptilogics, Inc.BiotechnologySeries B$1.2B83%
Frequently asked
How much funding has Athersys, Inc / New raised?
Athersys, Inc / New has raised approximately $12.5M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Athersys, Inc / New's estimated valuation?
Provath's modeled valuation for Athersys, Inc / New is approximately $33.2M (modeled range $3.9M–$94.7M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Athersys, Inc / New at?
Athersys, Inc / New's latest modeled financing stage is Series A. Its most recent recorded round closed around Tue Apr 18.
What does Athersys, Inc / New do and where is it based?
Athersys, Inc / New operates in the Biotechnology sector, based in CLEVELAND.
Explore related

See where Athersys, Inc / New sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Athersys, Inc / New, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.